Koninklijke Philips (PHIA) Q3 2024 earnings summary

Executive summary

• Profitability and margins improved strongly in Q3 2024, with flat sales as growth outside China offset deteriorating demand in China.

• Adjusted EBITDA margin reached 11.8%, up 160 basis points year-over-year, driven by innovation, productivity, and higher royalty income.

• Free cash flow was €22 million for the quarter, with full-year guidance revised downward for sales but maintained at the upper end for margins.

• Execution of the three-year plan remains ahead of schedule, with continued focus on operational improvement and patient safety.

• Net income increased to €181 million from €90 million in Q3 2023, mainly due to higher gross margin and lower Respironics field action costs.

Financial highlights

• Q3 2024 sales were €4,377M, down from €4,471M in Q3 2023; comparable sales growth was flat year-over-year.

• Adjusted EBITA was €516M (11.8% margin), up from €456M (10.2%); adjusted EBITDA margin was 16.8% (up from 15.5%).

• Net debt stood at €6.5 billion, with a leverage ratio of 2.2x net debt to adjusted EBITDA, improved from 2.5x a year ago.

• Productivity initiatives delivered €188 million in Q3 savings, totaling over €1.5 billion since January 2023.

• Operating cash flow was €192 million, with ending cash balance at €1.5 billion.

Outlook and guidance

• Full-year 2024 comparable sales growth expected at 0.5%-1.5% for the group, reflecting ongoing China weakness; growth outside China expected at 3%-5%.

• Adjusted EBITA/EBITDA margin for the year expected around 11.5%, at the upper end of the range.

• Free cash flow guidance for the year is ~€0.9 billion, at the lower end of the range.

• Segment outlook: Connected Care sales growth at the lower end of 3%-5% range; Diagnosis & Treatment to see slight growth; Personal Health flat to slight decline.

• Outlook excludes potential impact from ongoing Respironics legal proceedings.